Industry News: Biofortuna doubles its manufacturing capacity

The new facilities are designed to enable IVD and point of care businesses to develop and manufacture assays at scale

08 Nov 2021


Biofortuna, a specialist contract development and manufacturing partner to the in-vitro diagnostics (IVD) and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to a new state-of-the-art facility in Deeside, North Wales.

The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point of care businesses. 

The new premises provide 450m³ of class-leading, humidity-controlled clean room environments for the formulation, dispensing, manufacturing and analysis of more than 10 million reactions per week.

Dr. Nick Ash, Biofortuna Chief Executive Officer commented "This multi-million-pound investment demonstrates our ambition and commitment to become the sectors’ leading support specialist, helping our customers to accelerate their diagnostic development programs from concept to commercialization". 

Paul Williams, Head of Sales added "This facility will position Biofortuna as one of the leading outsourced providers of genomic services, custom assay development and contract manufacturing. It has been designed to expand our turn-key capabilities and provide our customers with a scalable resource to develop and manufacture their assays, particularly in the point of care and de-centralized IVD testing space".

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>